5-Fluorouracil iontophoretic therapy for Bowen's disease - 11/09/11

Doi : 10.1016/S0190-9622(97)80280-0

Mark L. Welch ^a : MAJ, William J. Grabski ^b : LTC, Martha L. McCollough ^b : LTC, Henry G. Skelton ^c : CAPT, Kathleen J. Smith ^d : COL, Padman A. Menon ^d : CDR, Lawrence L. Anderson ^b : LTC
^a Dermatology Service, Walter Reed Army Medical Center, Washington, Washington, D.C., Ft. Sam Houston, Texas, and Bethesda, Maryland, USA
^b Dermatology Service, Brooke Army Medical Center, Ft. Sam Houstonb, Washington, D.C., Ft. Sam Houston, Texas, and Bethesda, Maryland, USA
^c Dermatology Department, Armed Forces Institute of Pathology, Washington, Washington, D.C., Ft. Sam Houston, Texas, and Bethesda, Maryland, USA
^d Dermatology Service, Bethesda Naval Medical Center, Washington, D.C., Ft. Sam Houston, Texas, and Bethesda, Maryland, USA

Abstract

Background:

Topical 5-fluorouracil (5-FU) is an accepted therapy for Bowen's disease. Recurrences with this method have been attributed to deep follicular involvement and poor patient compliance because of the prolonged treatment time required.

Objective:

We sought to determine whether iontophoresis of 5-FU is an effective therapy for Bowen's disease.

Methods:

Twenty-six patients with biopsy-proven Bowen's disease received eight 5-FU iontophoretic treatments in 4 weeks. Local excision was done 3 months after the last treatment. The specimens were step-sectioned and evaluated for any histologic evidence of bowenoid changes.

Results:

Only 1 of 26 patients showed histologic evidence of Bowen's disease 3 months after treatment.

Conclusion:

5-FU iontophoresis appears to be a safe, effective, and well-tolerated therapy for Bowen's disease.

Le texte complet de cet article est disponible en PDF.

Export

Vol 36 - N° 6

P. 956-958 - juin 1997 Retour au numéro

Article précédent

Pentostatin (2′-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma
Daniela Greiner, Elise A. Olsen, Gina Petroni

| Article suivant

Adult pityriasis rubra pilaris: A 10-year case series
Beth D. Clayton, Joseph L. Jorizzo, Mike G. Hitchcock, Alan B. Fleischer, Phillip M. Williford, Steven R. Feldman, Wain L. White

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

5-Fluorouracil iontophoretic therapy for Bowen's disease - 11/09/11

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL